Friday, July 10, 2026

Drug profile · INN

meningococcal groups a, c, w-135 and y conjugate vaccine

meningococcal groups a, c, w-135 and y conjugate vaccine (NIMENRIX) is a immunostimulant.

EMA: approved Antiinfectives for systemic use (J07) J07AH08
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — meningococcal groups a, c, w-135 and y conjugate vaccine
Class
Antiinfectives for systemic use (J07)
Route
Patents
0
Programs
4
Data quality
0.83

Quick answer

meningococcal groups a, c, w-135 and y conjugate vaccine (NIMENRIX) is a immunostimulant.

Key facts

INN meningococcal groups a, c, w-135 and y conjugate vaccine
Brand NIMENRIX
Mechanism Immunostimulant
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07AH08

Mechanism of action

Immunostimulant

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. MEQ00089 Phase 3 · Sanofi Pasteur MSD · Healthy volunteers (Meningococcal infection)
  2. Nimenrix Phase 3 · GSK Glaxo Smith · Infections, Meningococcal
  3. 217043 Phase 2 · GSK Glaxo Smith · Infections, Meningococcal
  4. DNTH103-MG-201 Phase 2 · Dianthus Therapeutics, Inc · Generalized Myasthenia Gravis

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is meningococcal groups a, c, w-135 and y conjugate vaccine?

meningococcal groups a, c, w-135 and y conjugate vaccine (NIMENRIX) is a immunostimulant.

What is the brand name for meningococcal groups a, c, w-135 and y conjugate vaccine?

NIMENRIX is a marketed brand name for meningococcal groups a, c, w-135 and y conjugate vaccine. Check FDA Drugs@FDA for the current US label holder and prescribing information.